2024
Noninvasive in vivo photoacoustic detection of malaria with Cytophone in Cameroon
Yadem A, Armstrong J, Sarimollaoglu M, Kiki Massa C, Ndifo J, Menyaev Y, Mbe A, Richards K, Wade M, Zeng Y, Chen R, Zhou Q, Meten E, Ntone R, Tchuedji Y, Ullah S, Galanzha E, Eteki L, Gonsu H, Biris A, Suen J, Boum Y, Zharov V, Parikh S. Noninvasive in vivo photoacoustic detection of malaria with Cytophone in Cameroon. Nature Communications 2024, 15: 9228. PMID: 39455558, PMCID: PMC11511992, DOI: 10.1038/s41467-024-53243-z.Peer-Reviewed Original ResearchConceptsClearance of parasitemiaDetection of malariaMalaria-infected red blood cellsDiagnosed symptomatic casesCross-sectional cohortUncomplicated malariaMalaria diagnosticsMalaria infectionRed blood cellsSymptomatic casesTarget antigenAsymptomatic reservoirCameroonian adultsFlow cytometer platformBlood samplesReservoir of infectionBlood cellsLack sensitivityLongitudinal cohortMolecular assaysMalariaIRBCPoint-of-careCohortQuantitative PCRPersistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapy
2023
Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial sectionRepeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria
Foy B, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson C, Kittelson J, Slater H, Bousema T, Da O, Coulidiaty A, Colt M, Wade M, Richards K, Some A, Dabire R, Parikh S. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. JMIR Research Protocols 2023, 12: e41197. PMID: 36939832, PMCID: PMC10132043, DOI: 10.2196/41197.Peer-Reviewed Original ResearchIvermectin mass drug administrationMass drug administrationINTERNATIONAL REGISTERED REPORT IDENTIFIERMalaria incidenceDrug AdministrationMalaria transmissionIntense seasonal malaria transmissionMalaria controlSecondary safety outcomesParallel-group trialSeasonal malaria transmissionAdverse event monitoringActive case surveillancePrimary outcomeControl IINonpregnant individualsPostintervention changesTrial interventionCare interventionsSafety outcomesCluster RandomizedSubset of individualsCase surveillanceConsecutive daysEntomological assessments
2022
Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistanceClinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon
Hodson DZ, Mbarga Etoundi Y, Mbatou Nghokeng N, Mohamadou Poulibe R, Magne Djoko S, Goodwin J, Cheteug Nguesta G, Nganso T, Armstrong JN, Andrews JJ, Zhang E, Wade M, Eboumbou Moukoko CE, Boum Y, Parikh S. Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon. Malaria Journal 2022, 21: 298. PMID: 36273147, PMCID: PMC9588226, DOI: 10.1186/s12936-022-04315-2.Peer-Reviewed Original ResearchConceptsP. falciparum infectionPopulation attributable risk percentFalciparum infectionPlasmodium falciparum infectionYears of ageClinical characteristicsUrban hospitalMilitary HospitalAttributable risk percentHigher positivity rateLikelihood ratioRapid diagnostic testsMajor urban hospitalRural African settingConclusionsThe prevalenceHigh feverSymptomatic patientsHemoglobin levelsAnemia prevalenceSevere anemiaEmergency departmentVenous samplesClinical surveyPositivity rateWHO definition
2019
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. The Lancet 2019, 393: 1517-1526. PMID: 30878222, PMCID: PMC6459982, DOI: 10.1016/s0140-6736(18)32321-3.Peer-Reviewed Original ResearchConceptsMass drug administrationCluster-randomised trialIntervention groupMalaria episodesControl groupDrug AdministrationDetection cohortMass administrationIvermectin mass drug administrationUncomplicated malaria episodesClinical malaria episodesMalaria transmission seasonSingle oral dosesControl of malariaAdverse eventsCumulative incidencePrimary outcomeOral dosesEligible participantsAdverse reactionsFurther dosesTwo-armExclusion criteriaTransmission seasonTreatment phase
2016
Screening for Glucose-6-Phosphate Dehydrogenase Deficiency Using Three Detection Methods: A Cross-Sectional Survey in Southwestern Uganda.
Roh ME, Oyet C, Orikiriza P, Wade M, Mwanga-Amumpaire J, Boum Y, Kiwanuka GN, Parikh S. Screening for Glucose-6-Phosphate Dehydrogenase Deficiency Using Three Detection Methods: A Cross-Sectional Survey in Southwestern Uganda. American Journal Of Tropical Medicine And Hygiene 2016, 95: 1094-1099. PMID: 27672207, PMCID: PMC5094223, DOI: 10.4269/ajtmh.16-0552.Peer-Reviewed Original ResearchMeSH KeywordsChild, PreschoolCross-Sectional StudiesDiagnostic Tests, RoutineFemaleGene FrequencyGlucosephosphate DehydrogenaseGlucosephosphate Dehydrogenase DeficiencyHumansInfantMalariaMalaria, FalciparumMalaria, VivaxMalePoint-of-Care SystemsPrevalencePrimaquineRural PopulationSensitivity and SpecificityUgandaUrban PopulationConceptsG6PDd prevalenceGlucose-6-phosphate dehydrogenase deficiencyDehydrogenase deficiencySingle-dose primaquinePlasmodium falciparum transmissionSouthwestern UgandaPlasmodium ovale infectionNegative predictive valueMonths of ageCross-sectional surveyViable screening testOvale infectionsDiagnostic modalitiesStandard quantitative assayLow prevalenceRadical curePlasmodium vivaxPredictive valueSectional surveyCare testScreening testPrevalenceSevere deficiencyPrimaquineEnzyme activityAsymptomatic Plasmodium Infections in Children in Low Malaria Transmission Setting, Southwestern Uganda - Volume 22, Number 8—August 2016 - Emerging Infectious Diseases journal - CDC
Roh ME, Oyet C, Orikiriza P, Wade M, Kiwanuka GN, Mwanga-Amumpaire J, Parikh S, Boum Y. Asymptomatic Plasmodium Infections in Children in Low Malaria Transmission Setting, Southwestern Uganda - Volume 22, Number 8—August 2016 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2016, 22: 1494-1498. PMID: 27434741, PMCID: PMC4982177, DOI: 10.3201/eid2208.160619.Peer-Reviewed Original ResearchConceptsMicroscopy-positive samplesLow malaria transmission settingsInfectious Diseases journal - CDCAsymptomatic Plasmodium infectionsMalaria transmission settingsRapid diagnostic testsP. falciparum parasitesRoutine diagnostic testingP. ovale parasitesAsymptomatic childrenPlasmodium infectionPlasmodium malariaeP. malariaeTransmission settingsFalciparum parasitesDiagnostic testingDiagnostic testsMalariaeChildrenParasitesInfection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply